Chemical medicine

In regards to the chemical industry, Tiexi Pharmaceutical and Chemical Industry Cluster completed sales revenue of 28.1 billion yuan ($4.19 billion) in 2017, an increase of 5 percent, according to the Shenyang Economic and Information Technology Committee. The cluster's representative enterprises include Shenyang Chemical, Northeast Pharm, and Astellas.

Shenyang will speed up the development of chemical raw medicine and preparations, while also developing Chinese medicines and new drugs for the treatment of malignant tumors, as well as cardiovascular and cerebrovascular diseases by relying on the backbone enterprises. 

Additionally, the city will continue to focus on the development of therapeutic genetic engineering drugs and vaccines, as well as promote the construction of medical and health industrial parks in Neusoft cloud base and Xinmin Biopharmaceutical Industrial Park. 

By 2020, 10 enterprises with an annual sales income of more than 5 billion yuan ($796 million) will have been cultivated, and the output value of the biopharmaceutical industry will exceed 80 billion yuan.

Chemical medicine [Photo/VCG]